230
Participants
Start Date
December 4, 2023
Primary Completion Date
October 29, 2028
Study Completion Date
October 29, 2028
INCA033989
INCA033989 will be administered at protocol defined dose.
Ruxolitinib
Rux will be administered according to Prescribing Information/SmPC.
RECRUITING
Icahn School of Medicine At Mount Sinai, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Johns Hopkins Hospital, Baltimore
RECRUITING
Wake Forest Baptist Medical Center, Winston-Salem
RECRUITING
University of Miami Health System, Miami
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
The University of Kansas Cancer Center, Westwood
RECRUITING
Md Anderson Cancer Center, Houston
RECRUITING
City of Hope Medical Center, Duarte
RECRUITING
Stanford Cancer Institute, Palo Alto
RECRUITING
Dana Farber Cancer Institute, Boston
Lead Sponsor
Incyte Corporation
INDUSTRY